Pacira BioSciences, Inc. Common Stock

PCRXNASDAQUSD
25.58 USD
0.71 (2.86%)AT CLOSE (11:59 AM EDT)
26.38
0.80 (3.13%)
POST MARKET (AS OF 07:58 PM EDT)
Post Market
AS OF 07:58 PM EDT
26.38
0.80 (3.13%)
🔴Market: CLOSED

Shares of Pacira BioSciences, Inc. Common Stock (PCRX) are trading at $25.58. The technical outlook is "Neutral" and the fundamental picture shows "Neutral". This is driven by a bullish Golden Cross on the moving averages. Valuation metrics suggest PCRX is trading at a discount to its peers, earning an "Attractively Valued" rating.

Technical & fundamental data as of Aug 6, 2026.

Open?$24.90
High?$25.72
Low?$24.70
Prev. Close?$24.87
Volume?820.1K
Avg. Volume?596.7K
VWAP?$25.25
Rel. Volume?1.37x
Bid / Ask
Bid?$20.28 × 200
Ask?$27.50 × 100
Spread?$7.22
Midpoint?$23.89
Valuation & Ratios
Market Cap?991.4M
Shares Out?39.3M
Float?37.7M
Float %?95.8%
P/E Ratio?67.73
P/B Ratio?1.48
EPS?$0.37
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
Employees
829
Market Cap
991.4M
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2011-02-03
Address
2000 SIERRA POINT PARKWAY
BRISBANE, CA 94005
Phone: 650-242-8052
Technical OutlookNeutral
Strong SellNeutralStrong Buy
Long-Term (Tide)? Neutral(0/3)
Medium-Term (Wave)? Neutral(0/3)
Short-Term (Ripple)? Bearish(-2/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
60
Z-Score?
34
Momentum?
43
Short Sent.?
14
Piotroski F-Score?5/9Mixed
Altman Z-Score?1.95Grey
Confidence?64%Moderate
Full Fundamental Analysis →
Short InterestVery High
Short % of Float?18.48%High
Short Interest?7.0M
Days to Cover?15.8
Free Float37.7M
Avg Daily Volume441.2K
Settlement Date2026-07-15
Financial Health
Current Ratio?5.07Strong
Quick Ratio?3.96Strong
Cash Ratio?1.70Strong
Debt/Equity?0.54Moderate
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
89/100
P/E?
Peers
100
S&P
7
67.7PRICEY
P/B?
Peers
100
S&P
87
1.48CHEAP
P/S?
Peers
100
S&P
81
1.33CHEAP
P/FCF?
Peers
100
S&P
97
5.5CHEAP
EV/EBITDA?
Peers
100
S&P
75
10.9CHEAP
EV/Sales?
Peers
100
S&P
83
1.54CHEAP
Returns & Efficiency
ROE?
Peers
50
S&P
17
2.2%WEAK
ROA?
Peers
50
S&P
13
1.2%WEAK
Cash Flow & Enterprise
FCF?$179.5M
Enterprise Value?$1.1B
Fundamentals ratios updated end of day